New York University
Latest From New York University
University researchers will examine adenosine receptor modulator technology’s potential in C. difficile infection and atherosclerosis. CRISPR Therapeutics is partnering with University of Alabama-Birmingham to evaluate gene-editing procedures in Friedreich’s ataxia.
Collaboration with Washington University to co-develop therapies targeting apoliprotein A makes up part of Denali's big August push in Alzheimer's. Kleo gets global rights to two Yale antibody programs and raises Series A cash.
Combination therapies are the cornerstone of oncology, but the development model has been slow to shift to early testing of combinations of investigational drugs. The CoNNCT initiative aims to accelerate clinical testing of novel-novel combinations, and in doing so provide benefits for biopharma, clinicians and the cancer patients they serve.
Medical device and diagnostic companies are developing innovative new products for women with breast cancer designed to facilitate earlier diagnosis, improve diagnostic accuracy, increase surgical precision, and enable the least invasive, most breast-conserving approach to breast cancer surgery. With the number of breast cancer cases in the US projected to increase dramatically by 2030, the success of these technologies depends on their ability to improve cosmetic results and survival rates while lowering overall health care costs.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.